Testosterone treatment in older men: clinical implications and unresolved questions from the Testosterone Trials

The Lancet. Diabetes & Endocrinology
Bu B YeapMathis Grossmann

Abstract

A decrease in the concentration of circulating testosterone in many older men is a biomarker and possibly a rectifiable contributing factor to ill health. Low circulating testosterone concentration has been associated with cardiovascular disease, reduced cognition, fracture risk, and anaemia. However, randomised placebo-controlled trials are essential to clarify the benefits and possible risks of testosterone treatment in men without hypothalamic, pituitary, or testicular disease. The Testosterone Trials (T-Trials) were a coordinated set of trials that, following a screening-to-enrolment ratio of 65:1, randomly assigned 790 men aged 65 years or older who had a baseline testosterone concentration of less than 9·54 nmol/L and symptoms consistent with hypogonadism, but no recognisable hypothalamic-pituitary-testicular axis pathology, to daily transdermal testosterone or placebo for 12 months. In the main trial, testosterone treatment resulted in a modest benefit for sexual function, whereas the other primary outcomes of vitality and physical function were not met. Data from concomitant substudies raised a possible concern over changes in coronary plaque volume, showed a neutral effect on memory and other cognitive functions, and r...Continue Reading

Citations

Apr 19, 2019·Expert Opinion on Drug Safety·G CoronaM Maggi
Mar 11, 2020·The Journal of Clinical Endocrinology and Metabolism·Bu B YeapLeon Flicker
Dec 11, 2019·Journal of Cardiovascular Translational Research·Margarida LorigoElisa Cairrao
Jan 24, 2021·Endocrine Reviews·David J Handelsman
Apr 3, 2021·Frontiers in Endocrinology·Johnny S YounisZaid Abassi
Jan 4, 2022·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Ross J MarriottBu B Yeap

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Endocrine Reviews
Peter J SnyderSusan S Ellenberg
Clinical Trials : Journal of the Society for Clinical Trials
Peter J SnyderEvan Hadley
Journal of the American Geriatrics Society
David A Gruenewald, Alvin M Matsumoto
Nature Reviews. Endocrinology
Matthew SpitzerShalender Bhasin
The New England Journal of Medicine
Peter J SnyderTestosterone Trials Investigators
© 2022 Meta ULC. All rights reserved